Nektar Therapeutics (NASDAQ:NKTR) SVP Ivan P. Gergel sold 100,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $24.14, for a total transaction of $2,414,000.00. Following the completion of the sale, the senior vice president now owns 84,871 shares of the company’s stock, valued at approximately $2,048,785.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Nektar Therapeutics (NASDAQ NKTR) traded down 1.09% on Tuesday, reaching $24.50. 1,342,355 shares of the company’s stock were exchanged. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.93. The firm’s 50-day moving average price is $21.17 and its 200 day moving average price is $20.34. The company’s market cap is $3.83 billion.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.04). The company had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. Nektar Therapeutics’s revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.36) earnings per share. Equities research analysts predict that Nektar Therapeutics will post ($0.98) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/03/nektar-therapeutics-nktr-svp-ivan-p-gergel-sells-100000-shares.html.

A number of research firms recently weighed in on NKTR. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. BidaskClub raised Nektar Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Jefferies Group LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Nektar Therapeutics in a research report on Friday, July 21st. Finally, Evercore ISI initiated coverage on Nektar Therapeutics in a research report on Thursday, August 17th. They issued an “in-line” rating and a $20.00 price objective for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $26.80.

Hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Nektar Therapeutics by 14.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 692 shares during the period. LS Investment Advisors LLC grew its stake in Nektar Therapeutics by 8.8% during the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 535 shares in the last quarter. Flinton Capital Management LLC grew its stake in Nektar Therapeutics by 75.7% during the second quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 3,392 shares in the last quarter. Riverhead Capital Management LLC grew its stake in Nektar Therapeutics by 78.7% during the second quarter. Riverhead Capital Management LLC now owns 8,754 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 3,854 shares in the last quarter. Finally, Bank of Montreal Can grew its stake in Nektar Therapeutics by 21.8% during the first quarter. Bank of Montreal Can now owns 8,195 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 1,464 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.